Evidence map›Paper›PMID 37278154›Full record

ArticleJournal of diabetes science and technology2024

The Importance of Fructosamine for Monitoring the Compensation and Effectiveness of Diabetes Treatment.

Natalya Akhetova, Zhangentkhan Abylaiuly, Svetlana Bolshakova

Open access · greenAbstract read
In one paragraph

Article in Journal of diabetes science and technology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Natalya AkhetovaDepartment of Endocrinology, Asfendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan.ORCID 0009-0008-3398-2609
Zhangentkhan AbylaiulyDepartment of Endocrinology, Asfendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan.
Svetlana BolshakovaDepartment of Endocrinology, Asfendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan.
Kazakh National Medical University · KZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of fructosamine to assess the glycemic control represents a new step in diagnostics, and it has been accompanied by the active scientific discussion in recent years. That is why the purpose of this work is to study the average level of fructosamine in apparently healthy individuals and individuals with diabetes mellitus (DM), as well as the possibility to use it when evaluating the effectiveness of inpatient treatment of patients with hyperglycemia on the seven to ten days of hospitalization.

methodsThis research work was carried out in Alma-Ata, Republic of Kazakhstan, based on the endocrinology department in the period from 2020 to 2022. The work consists of a retrospective analysis of previously examined patients and a prospective stage. The statistical evaluation was carried out with the calculation of reliability coefficient, confidence interval, and criteria for testing for normality. The level of fructosamine in healthy individuals in the corresponding region was analyzed in this article for the first time, and the correlation between this indicator and the level of glycated hemoglobin was found.

resultsThe effectiveness of treatment of the Type 2 DM (according to the treatment protocol) has also been studied in stationary conditions for the seven to ten days, which makes it possible to judge the effectiveness of the prescribed therapy.

conclusionsThese results will allow identifying the irrationality of the prescribed therapy at an early stage, which is especially important for the correct management of patients with this pathology, and minimizing the possible complications.

Indexed as

Diabetes Mellitus, Type 2FructosamineGlycated HemoglobinAdultAgedBiomarkersBlood GlucoseFemaleGlycemic ControlHumansHypoglycemic AgentsKazakhstanMaleMiddle AgedProspective StudiesRetrospective StudiesBiomarkersBlood GlucoseFructosamineGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic Agentsglycated hemoglobinhospital treatmenthyperglycemiaserum glucosetarget indicatorsthe duration of disease

Identifiers

PMID37278154
PMCPMC11531054
OpenAlexW4379508992

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.